Abstract:INTRODUCTION Malignant gliomas consist of heterogenous cellular components that have adopted multiple overlapping escape mechanisms that overcome both targeted and immune-based therapies. The receptor for advanced glycation end products (RAGE) is a member of the immunoglobulin superfamily that is activated by diverse proinflammatory ligands present in the tumor microenvironment (TME). Activation of RAGE by its ligands stimulates multiple signaling pathways that are important in tumor growth, invasion, and immune escape. OBJECTIVE We aimed to demonstrate that blockade of RAGE expression may tackle resistance pathways by inhibiting GBM progression, invasion, and immune evasion. METHODS We evaluated genetic ablation of RAGE on the tumorigenicity of two syngeneic murine glioma models. RAGE expression was inhibited in the GL261 and K-Luc gliomas by shRNA and CRSPR/Cas9 techniques prior to intracranial implantation. Tumor growth, invasion, and inflammatory responses were examined by immunohistochemistry, qPCR, ELISA, western blotting, NanoString, flow cytometry, and in vivo survival analysis. RESULTS Intracellular RAGE ablation abrogated glioma growth and invasion by suppressing AKT and ERK1/2 activities and by downregulating MMP9 expression. Interestingly, RAGE inhibition also enhanced tumor inflammatory responses by downregulating the expression of galectin-3, rendered the immunotherapy resistant K-Luc gliomas responsive to immune checkpoint blockade therapy, and significantly increased survival. CONCLUSION This study is the first to link RAGE expression with galactin-3 as an immune modulator in glioblastoma and revealed that the effect of glioma RAGE expression on TME was mediated through downregulation of Gal-3 and subsequent polarization of Tumor-associated macrophages. The therapeutic significance of RAGE downregulation was demonstrated by sensitizing a highly invasive and immune-resistant glioma model to immune checkpoint blockade and strongly supports the development of RAGE ablation as a complementary treatment strategy for malignant gliomas.

Supplementary Figure 2 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Supplementary Figure 1 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Data from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

Rage Expression In Tumor-Associated Macrophages Promotes Angiogenesis In Glioma

Supplementary Table 1 from RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma

IMMU-08. RAGE ABLATION ATTENUATES GLIOMA PROGRESSION AND ENHANCES TUMOR IMMUNE RESPONSES BY SUPPRESSING GALECTIN-3 EXPRESSION

378 RAGE Ablation Attenuates Glioma Progression and Enhances Tumor Immune Responses by Suppressing Galectin-3 Expression

Supplementary Figures from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages

Supplementary Figure from Β2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages

Supplementary Data 1 from Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages

Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization

Supplementary Figure 7 from Acquired Resistance to Anti-VEGF Therapy in Glioblastoma is Associated with a Mesenchymal Transition

Abstract B44: Regulation of Macrophage Activation by Vascular Niche in Glioblastoma

Supplementary Methods and Supplementary Figures 1 Through 14 from Oligodendrocyte Progenitor Cells Promote Neovascularization in Glioma by Disrupting the Blood–Brain Barrier

Supplementary Figures 1-2 from Systemic Overexpression of Angiopoietin-2 Promotes Tumor Microvessel Regression and Inhibits Angiogenesis and Tumor Growth

Supplementary Figure 1 from Neutrophils Promote the Malignant Glioma Phenotype Through S100A4

Supplementary Figure 1 from Activating Peroxisome Proliferator-Activated Receptor Γ Mutant Promotes Tumor Growth in Vivo by Enhancing Angiogenesis

FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells

Increase in Tumor-Associated Macrophages after Antiangiogenic Therapy is Associated with Poor Survival among Patients with Recurrent Glioblastoma.

Supplementary Figure 1 from Melanoma Proteoglycan Modifies Gene Expression to Stimulate Tumor Cell Motility, Growth, and Epithelial-to-Mesenchymal Transition